Cite
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
MLA
Sutera, Philip, et al. “Clinical and Genomic Differences Between Advanced Molecular Imaging-Detected and Conventional Imaging-Detected Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.” European Urology, vol. 84, no. 6, Dec. 2023, pp. 531–35. EBSCOhost, https://doi.org/10.1016/j.eururo.2023.04.025.
APA
Sutera, P., Song, Y., Van der Eecken, K., Shetty, A. C., English, K., Hodges, T., Chang, J., Fonteyne, V., Rana, Z., Ren, L., Mendes, A. A., Lumen, N., Delrue, L., Verbeke, S., De Man, K., Song, D. Y., Pienta, K., Feng, F. Y., Joniau, S., & Lotan, T. (2023). Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. European Urology, 84(6), 531–535. https://doi.org/10.1016/j.eururo.2023.04.025
Chicago
Sutera, Philip, Yang Song, Kim Van der Eecken, Amol C. Shetty, Keara English, Theresa Hodges, Jinhee Chang, et al. 2023. “Clinical and Genomic Differences Between Advanced Molecular Imaging-Detected and Conventional Imaging-Detected Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.” European Urology 84 (6): 531–35. doi:10.1016/j.eururo.2023.04.025.